Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

PHASE3RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cataracts Infantile
Interventions
DRUG

Clobetasol Propionate

Clobetasol propionate ophthalmic nanoemulsion 0.05 % is an oil-in-water (O/W), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w).

DRUG

Prednisolone acetate ophthalmic suspension, 1%

Microfine sterile ophthalmic suspension of dense and whitish appearance.

Trial Locations (1)

08950

RECRUITING

Hospìtal Sant Joan de Deu, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Salvat

INDUSTRY

NCT05724446 - Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population | Biotech Hunter | Biotech Hunter